zax.doi.bio/about

About doi.bio

Intelligence Augmentation for Molecular Discovery

doi.bio is a revolutionary platform that unifies AI-powered literature synthesis with interactive molecular context, designed specifically for structural biologists, computational chemists, and drug discovery teams.

Our Mission

We believe that the future of molecular discovery lies at the intersection of scientific literature and three-dimensional protein structures. Traditional tools force researchers to work in silos—reading papers in one application, viewing structures in another, and managing data in yet another system.

doi.bio changes this paradigm by creating a single, collaborative workspace where:

The Problem We Solve

Scattered Knowledge

PDFs, notes, and wikis rarely converge into reusable institutional memory. Scientists spend hours re-synthesizing context that was already discovered by their colleagues.

Disconnected Structure

Molecular viewers exist in isolation, forcing scientists to context-switch between literature insights and 3D analysis. This leads to missed opportunities and wasted cycles.

Opaque Automation

Scripts and pipelines run without capturing reasoning, creating compliance headaches and repeated mistakes.

Our Approach

doi.bio blends three core capabilities:

1. Knowledge Graph

AI extracts targets, ligands, assays, and key findings from papers—building an interlinked graph that stays synced with 3D structures. Click on a protein in your structure viewer, and instantly see all related papers and experimental data.

2. Live Molecular Context

PDB and AlphaFold structures load instantly, with pocket annotation, clash detection, and conservation analysis built in. No more downloading files and loading them manually—everything is one click away.

3. Workflow Automation

Trigger docking, molecular dynamics, or custom compute with one click. Results flow back into the narrative with full provenance, making it easy to understand what was tried and why.

Why Now?

AlphaFold has opened the floodgates, providing access to 200M+ predicted structures. But access alone isn't enough—teams need tools to operationalize these predictions, not just view them.

The convergence of:

…makes this the perfect moment to build a unified platform for molecular discovery.

Our Team

doi.bio is founded by Steven Ness, a structural biochemist with a machine learning PhD and decades of software engineering experience. With deep expertise in PDB/AlphaFold ecosystems, molecular visualization, and AI-assisted research tools, Steven brings both domain knowledge and technical excellence to the platform.

We're assembling an advisory board of leaders across medicinal chemistry, platform engineering, business development, and regulatory strategy to accelerate delivery and ensure market fit.

Join Us

We're currently in private preview with select design partners. If you're working in structural biology, drug discovery, or computational chemistry and want to transform how your team works, get in touch.


doi.bio - Where papers meet proteins. Where teams move faster.